Junshi Biosciences Reports First Patient Dosed in Phase 3 JS207 Trial
Junshi Biosciences says the Phase 3 trial is testing JS207 in combination with JS007 as first-line treatment for advanced hepatocellular carcinoma.
Story updates
11:07:59 AM UTC
SquawkNews
Shanghai Junshi Biosciences dosed the first patient in a Phase 3 trial of JS207 + JS007 vs toripalimab + bevacizumab in first-line advanced hepatocellular carcinoma, targeting PFS and OS with a planned 560 patients.Material DetailsContext by AI AnalystThis is an early pivotal step building on Phase…